Advisory

Team Members

Chris Kim, JD, LL.M., SJD (C)
Chief Executive Officer & Chairman

Chief Executive Officer and Chairman of Liminatus Pharma, Inc. (Nasdaq: LIMN), with more than 30 years of experience in corporate finance, M&A, intellectual property, cross-border transactions, and strategic investments. Has advised numerous U.S. and international companies and served as legal counsel to Korean small- and mid-sized companies in connection with IPOs and public-market transactions. Has participated in more than $500 million in investments across private and publicly traded companies and was a Founding Investor of Zura Bio Ltd. (Nasdaq: ZURA). Received his LL.M. and pursued SJD studies at the University of Pennsylvania Law School. Completed executive programs at Harvard Business School and Saïd Business School, University of Oxford

Scott Dam
CFO

Has served as Managing Director at Raymond James and Head of Asia Healthcare Investment Banking, and held senior positions at Jefferies and Credit Suisse in the U.S. and Asia. Extensive experience in cross-border M&A, capital markets, and strategic advisory within the healthcare and biopharma sectors.Holds an MBA from INSEAD and a CFA designation.

Eun Sook Lee, MD/PhD
Director

Has served as the President and Institute Director of the National Cancer Center, Republic of Korea and President of the Graduate School of Cancer Science and Policy at the National Cancer Center, Republic of Korea Honorary Professor at the Graduate School of Cancer Science and Policy, National Cancer Center, Republic of Korea; Director of Surgery at Lily Yoo Hospital; and a member of the National Academy of Medicine of Republic of Korea.

Ji Yeon Baek, MD/PhD
Medical Director

Has served as the medical oncologist and clinical research doctor of the National Cancer Center, Republic of Korea.

Sang-Jin Daniel Lee, PhD
SAB

Has served as the Director of Animal Experimental Facility of the Research Institute of National Cancer Center, Republic of Korea and Professor of the Graduate School of Cancer Science and Policy at the National Cancer Center, Republic of Korea. Has also served as the Coordinator of The Korean Association of Immune Cell Engineering and Therapy. Professor at the Graduate School of Cancer Science and Policy, National Cancer Center, Republic of Korea; Senior Researcher of the Research Institute of National Cancer Center, Republic of Korea

Byong Chul Yoo, PhD
SAB

Former Principal Researcher at the National Cancer Center, Republic of Korea, where he served for over 20 years since joining as one of the earliest members in 2002. Expert in biochemistry, proteomics, and metabolomics, with a focus on anticancer drug resistance and biomarker discovery. Author of two books and over 130 publications including Nature, and recipient of multiple national awards.

BeomKyu Choi PhD
SAB

Has served as Principal Scientist at the National Cancer Center, Republic of Korea, and as Chief of the Biomedicine Production Branch (cGMP facility). An expert in immunology and advanced biopharmaceutical development, including immune checkpoint inhibitors and gene and cell therapies (GCT).
회원가입
아이디/비밀번호 찾기